Cargando…

Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China

OBJECTIVE: The study aimed to conduct clinical and economic evaluation of salvianolate injection for patients with coronary heart disease (CHD) in comparison to Danhong injection and alprostadil injection. METHOD: This was a retrospective study using National Health Insurance Data about inpatients d...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lisong, Chen, Xiaolan, Oi Lam Ung, Carolina, Zhu, He, Hu, Hao, Han, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314915/
https://www.ncbi.nlm.nih.gov/pubmed/32625090
http://dx.doi.org/10.3389/fphar.2020.00887
_version_ 1783550153049767936
author Yang, Lisong
Chen, Xiaolan
Oi Lam Ung, Carolina
Zhu, He
Hu, Hao
Han, Sheng
author_facet Yang, Lisong
Chen, Xiaolan
Oi Lam Ung, Carolina
Zhu, He
Hu, Hao
Han, Sheng
author_sort Yang, Lisong
collection PubMed
description OBJECTIVE: The study aimed to conduct clinical and economic evaluation of salvianolate injection for patients with coronary heart disease (CHD) in comparison to Danhong injection and alprostadil injection. METHOD: This was a retrospective study using National Health Insurance Data about inpatients diagnosed with CHD in China in 2015 who met the inclusion criteria. The recruited patients were divided into two samples: surgery and non-surgery. The exposed group received salvianolate injection, while the control group received either alprostadil injection or Danhong injection. The medical cost per hospitalization, hospitalization duration, and the rehospitalization rates were used as outcome indicators. Heterogeneity was processed according to disease stratification. Propensity score matching and multivariate analysis were used for statistical analysis to control potential confounding factors. RESULTS: The hospitalization duration of salvianolate injection group was significantly (P < 0.05) shorter than that of Danhong injection group in the non-surgery sample. The hospitalization duration of salvianolate injection group was significantly (P < 0.05) shorter than those of alprostadil injection group in both surgery and non-surgery samples. In the non-surgery sample, the medical cost per hospitalization of salvianolate injection group was significantly (P < 0.05) lower than that of alprostadil injection group. However, there were no statistical differences of rehospitalization rates in salvianolate injection group versus alprostadil injection group or salvianolate injection group versus Danhong injection group in both surgery and non-surgery samples. CONCLUSION: Salvianolate injection showed advantages in reducing hospitalization duration for inpatients with CHD when comparing with alprostadil injection and Danhong injection. The results of this real-world study can help to inform clinical practice for CHD patients.
format Online
Article
Text
id pubmed-7314915
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73149152020-07-02 Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China Yang, Lisong Chen, Xiaolan Oi Lam Ung, Carolina Zhu, He Hu, Hao Han, Sheng Front Pharmacol Pharmacology OBJECTIVE: The study aimed to conduct clinical and economic evaluation of salvianolate injection for patients with coronary heart disease (CHD) in comparison to Danhong injection and alprostadil injection. METHOD: This was a retrospective study using National Health Insurance Data about inpatients diagnosed with CHD in China in 2015 who met the inclusion criteria. The recruited patients were divided into two samples: surgery and non-surgery. The exposed group received salvianolate injection, while the control group received either alprostadil injection or Danhong injection. The medical cost per hospitalization, hospitalization duration, and the rehospitalization rates were used as outcome indicators. Heterogeneity was processed according to disease stratification. Propensity score matching and multivariate analysis were used for statistical analysis to control potential confounding factors. RESULTS: The hospitalization duration of salvianolate injection group was significantly (P < 0.05) shorter than that of Danhong injection group in the non-surgery sample. The hospitalization duration of salvianolate injection group was significantly (P < 0.05) shorter than those of alprostadil injection group in both surgery and non-surgery samples. In the non-surgery sample, the medical cost per hospitalization of salvianolate injection group was significantly (P < 0.05) lower than that of alprostadil injection group. However, there were no statistical differences of rehospitalization rates in salvianolate injection group versus alprostadil injection group or salvianolate injection group versus Danhong injection group in both surgery and non-surgery samples. CONCLUSION: Salvianolate injection showed advantages in reducing hospitalization duration for inpatients with CHD when comparing with alprostadil injection and Danhong injection. The results of this real-world study can help to inform clinical practice for CHD patients. Frontiers Media S.A. 2020-06-18 /pmc/articles/PMC7314915/ /pubmed/32625090 http://dx.doi.org/10.3389/fphar.2020.00887 Text en Copyright © 2020 Yang, Chen, Oi Lam Ung, Zhu, Hu and Han http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yang, Lisong
Chen, Xiaolan
Oi Lam Ung, Carolina
Zhu, He
Hu, Hao
Han, Sheng
Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China
title Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China
title_full Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China
title_fullStr Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China
title_full_unstemmed Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China
title_short Clinical and Economic Evaluation of Salvianolate Injection for Coronary Heart Disease: A Retrospective Study Based on National Health Insurance Data in China
title_sort clinical and economic evaluation of salvianolate injection for coronary heart disease: a retrospective study based on national health insurance data in china
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314915/
https://www.ncbi.nlm.nih.gov/pubmed/32625090
http://dx.doi.org/10.3389/fphar.2020.00887
work_keys_str_mv AT yanglisong clinicalandeconomicevaluationofsalvianolateinjectionforcoronaryheartdiseasearetrospectivestudybasedonnationalhealthinsurancedatainchina
AT chenxiaolan clinicalandeconomicevaluationofsalvianolateinjectionforcoronaryheartdiseasearetrospectivestudybasedonnationalhealthinsurancedatainchina
AT oilamungcarolina clinicalandeconomicevaluationofsalvianolateinjectionforcoronaryheartdiseasearetrospectivestudybasedonnationalhealthinsurancedatainchina
AT zhuhe clinicalandeconomicevaluationofsalvianolateinjectionforcoronaryheartdiseasearetrospectivestudybasedonnationalhealthinsurancedatainchina
AT huhao clinicalandeconomicevaluationofsalvianolateinjectionforcoronaryheartdiseasearetrospectivestudybasedonnationalhealthinsurancedatainchina
AT hansheng clinicalandeconomicevaluationofsalvianolateinjectionforcoronaryheartdiseasearetrospectivestudybasedonnationalhealthinsurancedatainchina